Premium
Renal clearance of canrenoate in normal man
Author(s) -
Hofmann Lorenz M.,
Polk Rothwell C.,
Maibach Howard I.
Publication year - 1975
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1975186748
Subject(s) - endocrinology , medicine , glucuronide , aldosterone , metabolite , excretion , chemistry , renal function , plasma renin activity , pah clearance , renin–angiotensin system , renal blood flow , effective renal plasma flow , blood pressure
Potassium canrenoate was administered intravenously, twice at a 9‐hr interval, to 3 apparently healthy male volunteers. No consistent changes in endogenous creatinine or PAH clearances were observed for 6 hr after the initial 200‐mg dose of this aldosterone antagonist. The clearance of canrenone (the major γ‐lactone metabolite) exceeded by 70% the simultaneous clearance of creatinine from the second through the sixth hour. The excretion of canrenone amounted to 6.8 mg (3.4%) of the dose during the 6‐hr clearance study, but was nearly absent (0.2 mg) during the ensuing 6‐ to 9‐hr period. The cumulative excretion of the glucuronide conjugate of canrenone amounted to 4.6 and 2.8 mg (2.3% and 1.4%) of the dose during these respective periods. A sustained retention of K was observed in 1 subject. Otherwise, as was anticipated in the absence of hyperaldosteronism, urinary electrolyte levels were essentially unchanged. Circulating aldosterone and plasma renin activity levels were essentially unaltered.